Measles spreads to sixth New Mexico county
(Rimma Bondarenko/ Getty Images)
The New Mexico health department on Thursday reported the first cases of measles in Sandoval County, the sixth county where the highly contagious disease has been detected. The two new cases included an adult of unknown vaccination status and an unvaccinated child under the age of four.
Presbyterian Rust Hospital Emergency Department (2400 Unser Boulevard SE in Rio Rancho):
Wednesday, April 30 from noon – 5:30 p.m.
Sunday, May 11 from 7:30 a.m. – 1 p.m.
Presbyterian Rust Medical Center Hematology/Oncology Clinic, 2400 Unser Boulevard SE in Rio Rancho:
Thursday, May 1 from 2 p.m. – 4:30 p.m.
Trader Joe's grocery store (8928 Holly Ave. NE in Albuquerque):
Tuesday, May 6 from 10:30 a.m. – 1 p.m.
Ribs Hickory Pit BBQ (12220 NM-14 in Cedar Crest)
Saturday, May 10 from noon – 3 p.m.
DOH also reported several locations, days and times during which residents may have been exposed to measles.
'If you have been exposed to measles and are vaccinated, your risk of getting sick is low,' NMDOH Chief Medical Officer Dr. Miranda Durham said in a statement. 'Watch for symptoms but know that the vaccine is very good at preventing measles.'
Measles symptoms begin with a cough, runny nose and eye redness, before progressing to fever and rash that starts at the head before moving down the body. Health officials advise that people who have measles can infect others from four days before the rash appears and remain contagious four days after the rash is gone.
With the new cases in Sandoval County, New Mexico now amassed 73 cases, with others in: Chaves, Curry, Doña Ana, Eddy and Lea counties. Currently, more than 1,000 measles cases have been reported nationwide, according to the Centers for Disease Control and Prevention.
The health department encourage people with symptoms who have been exposed to measles to call NMDOH Helpline at 1-833-SWNURSE (1-833-796-8773) for guidance in English and Spanish. If planning to see a doctor or visit an emergency room, call first so health care providers can plan for a visit by someone who may have measles.
Lastly, the Sandoval County Public Health Office (1500 Idalia Road NE in Bernalillo) offers the measles, mumps, rubella vaccination with no appointment necessary from 8:30 a.m to 11:30 a.m. and 1:30 p.m. to 3:30 p.m. Mondays – Thursdays. For more information call (505) 867-2291, extension 1707.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET> English session: 7:00pm CEST / 1:00pm ET> During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Sign in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET > English session: 7:00pm CEST / 1:00pm ET > During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", 'expect', "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", 'potential', "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.
New York Post
5 hours ago
- New York Post
Here are the small things that are causing your anxiety to skyrocket — and your health to worsen
Simply spotting a nemesis, loud chewing and heavy breathing are some of the smallest things that will push Americans over the edge, according to new research. A survey asked 2,000 adults about their lowest common denominator of stress and revealed that the smallest sounds or acts are enough to send their anxiety skyrocketing. Lagging WiFi (40%) and an unexpected phone call (35%) also ranked high on the list. 6 A survey asked 2,000 adults about their lowest common denominator of stress and revealed that the smallest acts are enough to send their anxiety skyrocketing. Getty Images/iStockphoto Americans outlined some of the weirdest causes of stress: 'the texture of my socks,' 'aluminum cans,' 'not washing my hair for two days' and 'the beeping sound on TV to hide swearing' were among the most unique. To pile on, just thinking about how expensive everything has gotten (47%), running late when stuck in traffic (40%) and simple miscommunications (39%) are common stressful situations. Conducted by Talker Research on behalf of CBDfx, results also revealed what Americans do when they need to mellow out. Many turn to music (58%), deep breathing and meditation (34%) or pet cuddles (32%). 6 Just thinking about how expensive everything has gotten (47%), running late when stuck in traffic (40%) and simple miscommunications (39%) are common stressful situations. SWNS In fact, Americans would rather hear their favorite artist or band over their partner (46% vs 34%) when they need to de-stress. The average American has stuck to their unwinding method for over a decade, which may be because 84% find these approaches effective. The survey, which polled respondents who have all tried CBD or THC before, also found that 20% take CBD gummies and 30% use THC products on a daily basis in order to combat their stress. And it's working: Users find that their stress levels are decreased by an average of 54% after taking a CBD gummy, while THC users find they drop by more than two-thirds (68%). 6 The average American has stuck to their unwinding method for over a decade, which may be because 84% find these approaches effective. SWNS Nearly three in five (58%) respondents believe that there's less stigma surrounding CBD and THC products today, compared to 10 years ago. But compared to just five years ago, two-thirds (67%) find themselves getting stressed easier. This may be why another two-thirds (67%) agree that Americans would be less stressed out if they all indulged in some CBD or THC. 6 The survey found that 20% take CBD gummies and 30% use THC products on a daily basis in order to combat their stress. SWNS 'One of the benefits of CBD's interaction with the body's endocannabinoid system is a calming effect that works great for dialing down stress,' said Jameson Rodgers, CBDfx Co-Founder. 'THC can have similar positive effects—enhanced by the compound's natural mood elevation benefits—making it another great choice for stress relief.' Seventy-three percent of Americans say that stress has an impact on their quality of life and an even larger number (77%) said it has an impact on their quality of sleep. In fact, only 20% of Americans admit they don't look at their phone past a certain time each night and even fewer (11%) avoid looking at it before a certain time in the morning. 6 Nearly three in five (58%) respondents believe that there's less stigma surrounding CBD and THC products today, compared to 10 years ago. SWNS To combat this, the average respondent takes CBD gummies an average of three nights a week, while 16% say it's a nightly occurrence. They also average using THC products four nights each week, with 29% doing so nightly. 'Over time, lack of sleep can have a negative effect on many areas of a person's overall health, including stress. When you're tired, stress can be more difficult to manage and, potentially, can do more long-term damage,' said Rodgers. 'CBD sleep products can be an effective natural sleep aid. Those same calming effects that make CBD great for stress relief also make it an effective base ingredient for sleep aids, along with compounds like CBN (cannabinol), melatonin, chamomile, and other natural ingredients. THC works well with those same natural sleep ingredients, helping to elevate one's mood and help them relax before bedtime.' 6 Seventy-three percent of Americans say that stress has an impact on their quality of life and an even larger number (77%) said it has an impact on their quality of sleep. SWNS TOP 10 SMALLEST THINGS/SOUNDS THAT CAUSE AMERICANS STRESS When I see someone that I don't want to talk to – 46% A knock on the front door when I'm not prepared for guests – 44% People talking to me when I want silence – 43% When my Wi-Fi is lagging or cuts out – 40% Listening to someone chewing loudly – 40% Phone calls when I'm not expecting one – 34% Someone near me heavy breathing – 25% My alarm clock/alarm – 21% Text message alerts – 16% My phone/notifications going off during a meeting – 15% Survey methodology: Talker Research surveyed 2,000 Americans who've ever tried CBD or THC; the survey was commissioned by CBDfx and administered and conducted online by Talker Research between April 30 and May 8, 2025.
